In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dynavax Technologies Corporation

http://www.dynavax.com

Latest From Dynavax Technologies Corporation

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Japan Q3 Roundup: Daiichi Emerges As Growth Leader While Others Balance Ups And Downs

The success of Enhertu led Daiichi Sankyo to raise its annual forecast for the fiscal year ending 31 March, while Eisai is readying for Leqembi’s steady US growth. Meanwhile, Astellas, Chugai and Shionogi balanced growth for some products with declines for others.

Japan Sales & Earnings

Glenmark Leaps Into Sub-Q Checkpoint Inhibitor Terrain With China Deal

India-China combine for subcutaneously injected PD-L1 inhibitor takes wings, with Glenmark set to take Alphamab/3D Med’s envafolimab to key emerging markets, widening access for patients.

Research & Development ImmunoOncology

FDA’s Califf Is ‘Very Worried’ About Judges Overruling Agency Decisions

Commissioner says more judges have recently stepped in and ‘acted like they were FDA.’ Concern is heightened as Supreme Court is to rule on whether to overturn or limit Chevron deference to agency decisions.

Legal Issues FDA
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
  • Other Names / Subsidiaries
    • Symphony Dynamo, Inc. (SDI)
UsernamePublicRestriction

Register